REGENXBIO Inc. — FY 2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The filing also reports unaudited fourth-quarter results. REGENXBIO is a clinical-stage gene-therapy company that licenses its NAV AAV-vector platform and develops its own candidates. Its revenue is primarily licensing and royalties; it had no product sales of its own.
Financial results and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $35.2 million | $218.5 million |
| Operating expenses | $184.2 million | $130.4 million |
| Operating income (loss) | $(149.0) million | $88.1 million |
| Net income (loss) | $(94.7) million | $99.9 million |
| Net income (loss) per diluted share | $(2.58) | $2.73 |
| Operating cash flow | $(107.7) million | $104.6 million |
- Gross profit, calculated as revenue less cost of revenues, was $27.0 million, or approximately 76.6% of revenue. Operating margin was approximately negative 423.0%; the comparable 2018 operating margin was approximately 40.3%.
- Fourth-quarter 2019 revenue was $11.8 million and net loss was $26.5 million.
- At year-end, cash and cash equivalents were $69.5 million and marketable securities were $330.5 million, totaling $400.0 million. Working capital was $311.4 million.
- Total liabilities were $47.7 million; the filing reports no conventional borrowings in the presented balance sheet. Recognized operating lease liabilities were $11.3 million. Contractual minimum lease payments were $127.2 million, including estimated payments on the future headquarters lease.
- Management expected year-end cash, cash equivalents and marketable securities to fund operations and capital needs for at least 12 months from the filing date, based on its business plan. The company expected continued losses and said additional capital would be needed to achieve its objectives.
Material changes versus the prior year
- Revenue fell by $183.3 million, mainly because 2018 included $176.1 million of non-recurring license revenue from the AveXis amendment and $35.6 million from the Abeona license. In 2019, Zolgensma commercial royalties contributed $20.8 million.
- Research and development expense rose 48% to $124.2 million, while general and administrative expense increased to $51.8 million. The company cited higher staffing, clinical and preclinical work, manufacturing-related spending and professional services.
- Investment income rose to $48.6 million, including $31.8 million in unrealized gains and $6.0 million in realized gains on Prevail shares. These market-value gains boosted reported results but did not offset the operating loss.
- Operating cash flow swung from positive $104.6 million to negative $107.7 million, principally reflecting the absence of large 2018 AveXis payments and increased operating costs.
Business outlook, risks and notable items
- Pipeline: RGX-314 had positive interim subretinal wet-AMD data reported in 2019; the company planned a pivotal program in the second half of 2020 and Phase II studies of suprachoroidal delivery for wet AMD and diabetic retinopathy. RGX-121 was in Phase I/II for MPS II; RGX-111 was in Phase I for MPS I; RGX-501 was in Phase I/II for HoFH; RGX-181 remained preclinical for CLN2 disease.
- Safety and regulatory: FDA temporarily placed the RGX-314 wet-AMD trial on partial clinical hold while it reviewed third-party delivery devices; the hold was subsequently removed without changes to the delivery system. Earlier RGX-501 transaminase elevations led to an expanded cohort using steroid prophylaxis; no significant liver-enzyme elevations or serious adverse events were reported in that expanded cohort as of year-end.
- Manufacturing: Construction of a Rockville cGMP facility intended to support clinical and commercial production at scales up to 2,000 liters was underway; operations were expected to begin in 2021. The company also relies on external manufacturers.
- Key risks: Clinical and regulatory outcomes remain uncertain; revenue depends on a small number of licensees and contingent payments; development requires substantial spending and may require further financing. Manufacturing execution, competition, intellectual-property rights and reimbursement for potentially high-cost one-time therapies are additional risks.
- Concentration and contingencies: Three customers accounted for approximately 92% of 2019 revenue. The company disclosed no pending legal action expected to have a material adverse effect and no off-balance-sheet arrangements. Its auditor issued an unqualified opinion on the financial statements and internal controls, while identifying license-revenue assessment of substantive termination penalties as a critical audit matter because it required significant judgment.
Investor verification checklist
- Confirm the timing and substance of subsequent RGX-314, RGX-121 and RGX-501 trial updates, and any regulatory actions.
- Assess how much future revenue depends on Zolgensma royalties, the $80 million sales milestone, and a limited number of licensees.
- Separate recurring operating performance from one-time license revenue and volatile Prevail investment gains.
- Review cash burn, planned facility spending, lease commitments and the assumptions behind management’s stated 12-month funding horizon.
- Verify the status of RGX-501 liver-safety monitoring and the clinical and manufacturing risks associated with advancing gene therapies.